64 results
Keyword Erbitux Remove keyword
-
List item
Withdrawn application: Erbitux
cetuximab, date of withdrawal: 17/09/2012, Post-authorisation, Last updated: 22/11/2012Erbitux: Withdrawn application … marketing authorisation for Erbitux (cetuximab) On 17 September … marketing authorisation for Erbitux, to extend its use in the … -
List item
Human medicine European public assessment report (EPAR): Erbitux
cetuximab, Head and Neck Neoplasms; Colorectal Neoplasms
Date of authorisation: 29/06/2004, Revision: 29, Authorised, Last updated: 25/05/2022Erbitux Cancer Neoplasms Intestinal … Erbitux … Erbitux, INN-cetuximab EMA/13275/2014 … -
List item
Press release: Merck KGaA withdraws its application for an extension of the indication for Erbitux (cetuximab)
CHMP, Last updated: 19/09/2012extension of the indication for Erbitux (cetuximab … centrally authorised medicine Erbitux (cetuximab), 5-mg/ml solution … marketing authorisation for Erbitux to the treatment of non-small-cell … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 November 2011
CHMP, Last updated: 18/11/2011PDF icon application/pdf Erbitux cetuximab Merck KGaA … -
List item
Press release: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 16-19 November 2009
CHMP, Last updated: 20/11/2009Erbitux … extension of indication for Erbitux (cetuximab), from Merck KgaA … opinion that the indication of Erbitux should not be extended to … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 November 2013
CHMP, Last updated: 22/11/2013Erbitux INN cetuximab Marketing-authorisation … -
List item
Press release: Meeting highlights from the Committee for Medicinal Products for Human Use,27-30 May 2008
CHMP, Last updated: 02/06/2008Erbitux … approved medicines: • Erbitux (cetuximab), from Merck KGaA … intolerant to irinotecan. Erbitux is currently indicated in … -
List item
Human medicine European public assessment report (EPAR): Rybrevant
amivantamab, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 09/12/2021,
, 
, Revision: 2, Authorised, Last updated: 30/01/2023
-
List item
Human medicine European public assessment report (EPAR): Portrazza
necitumumab, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 15/02/2016,, Revision: 3, Withdrawn, Last updated: 27/07/2021
-
List item
Human medicine European public assessment report (EPAR): Bavencio
avelumab, Neuroendocrine Tumors
Date of authorisation: 18/09/2017,, Revision: 15, Authorised, Last updated: 24/03/2023
-
List item
Human medicine European public assessment report (EPAR): Taxotere
docetaxel, Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Prostatic Neoplasms; Stomach Neoplasms; Breast Neoplasms
Date of authorisation: 27/11/1995, Revision: 50, Authorised, Last updated: 24/03/2023 -
List item
Human medicine European public assessment report (EPAR): Keytruda
Pembrolizumab, Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Urologic Neoplasms; Endometrial Neoplasms
Date of authorisation: 17/07/2015, Revision: 50, Authorised, Last updated: 28/04/2023 -
List item
Human medicine European public assessment report (EPAR): Cyramza
Ramucirumab, Stomach Neoplasms
Date of authorisation: 19/12/2014, Revision: 15, Authorised, Last updated: 13/12/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 28 November - 1 December 2022
European Medicines Agency, Amsterdam, the Netherlands, from 28/11/2022 to 01/12/2022, Last updated: 03/04/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 4-7 July 2022
European Medicines Agency, Amsterdam, the Netherlands, from 04/07/2022 to 07/07/2022, Last updated: 31/03/2023 -
List item
PRAC: Agendas, minutes and highlights (updated)
Last updated: 07/06/2023 -
List item
Workshop: In vitro cytokine-release assays
London, 20/11/2009, Last updated: 20/11/2009anti-CD52), Rituxan (anti-CD20), Erbitux (anti-EGFR), Herceptin (anti-HER2 … with anti-CD3, Campath and Erbitux (increases in all 3 cytokines … anti-CD3, anti-CD28 SA, Campath, Erbitux, Herceptin, Zenapax and … -
List item
Committee for Medicinal Products for Human Use (CHMP): 21-24 March 2022
European Medicines Agency, Amsterdam, the Netherlands, from 21/03/2022 to 24/03/2022, Last updated: 12/08/2022 -
List item
CHMP: Agendas, minutes and highlights (updated)
Last updated: 06/06/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 June 2021
European Medicines Agency, Amsterdam, the Netherlands, from 07/06/2021 to 10/06/2021, Last updated: 07/06/2021 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 29-31 October 2012
European Medicines Agency, London, UK, from 29/10/2012 to 31/10/2012, Last updated: 03/12/2012 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 8-11 April 2013
European Medicines Agency, London, UK, from 08/04/2013 to 11/04/2013, Last updated: 02/06/2012 -
List item
Pharmacogenomics in oncology - Scientific guideline
Last updated: 01/04/2008 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 10-13 June 2013
European Medicines Agency, London, UK, from 10/06/2013 to 13/06/2013, Last updated: 02/07/2012 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 3-6 February 2014
European Medicines Agency, London, UK, from 03/02/2014 to 06/02/2014, Last updated: 13/08/2013